No Data
No Data
Lionco Pharmaceutical Gets Nod to Amend Cefuroxime Sodium for Injection's Production Standards
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Lionco Pharmaceutical Group (603669.SH): net loss of 40.4002 million yuan in the first half of the year.
On August 23, Gelonhui reported the semi-annual report for the year 2024, with revenue of 0.141 billion yuan, a year-on-year increase of 25.29%; net income attributable to shareholders of the listed company was -40.4002 million yuan.
Lionco Pharmaceutical Group (603669.SH): Subsidiary Cefoperazone Sodium for Injection passes the generic drug consistency evaluation.
On August 14, Gelonhui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary, Hainan Lionco Pharmaceutical Co., Ltd. (referred to as Lionco Pharmaceutical), recently received the approval notice of the supplementary drug application for the injection of cefoperazone sodium (referred to as the pharmaceutical) issued by the State Administration of Drug Administration. The pharmaceutical has passed the consistency evaluation of generic drug quality and efficacy. Cefoperazone sodium for injection is mainly used for: lower respiratory tract infections, urinary tract infections, abdominal infections, pelvic infections, sepsis, skin and soft tissue infections, bone and joint infections, and meningitis caused by pneumococcus or influenza bacillus.
Lionco Pharmaceutical's Unit to Trial Esomeprazole Magnesium Sodium Bicarbonate Dry Suspension
No Data